232 related articles for article (PubMed ID: 20508245)
1. Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.
Botten J; Sidney J; Mothé BR; Peters B; Sette A; Kotturi MF
Microbiol Mol Biol Rev; 2010 Jun; 74(2):157-70. PubMed ID: 20508245
[TBL] [Abstract][Full Text] [Related]
2. A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.
Kotturi MF; Botten J; Sidney J; Bui HH; Giancola L; Maybeno M; Babin J; Oseroff C; Pasquetto V; Greenbaum JA; Peters B; Ting J; Do D; Vang L; Alexander J; Grey H; Buchmeier MJ; Sette A
PLoS Pathog; 2009 Dec; 5(12):e1000695. PubMed ID: 20019801
[TBL] [Abstract][Full Text] [Related]
3. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans.
Botten J; Whitton JL; Barrowman P; Sidney J; Whitmire JK; Alexander J; Kotturi MF; Sette A; Buchmeier MJ
J Virol; 2010 Oct; 84(19):9947-56. PubMed ID: 20668086
[TBL] [Abstract][Full Text] [Related]
4. Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage.
Kotturi MF; Botten J; Maybeno M; Sidney J; Glenn J; Bui HH; Oseroff C; Crotty S; Peters B; Grey H; Altmann DM; Buchmeier MJ; Sette A
Immunome Res; 2010 May; 6():4. PubMed ID: 20478058
[TBL] [Abstract][Full Text] [Related]
5. Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.
Martinez-Sobrido L; de la Torre JC
Expert Rev Vaccines; 2016 Sep; 15(9):1113-21. PubMed ID: 27118328
[TBL] [Abstract][Full Text] [Related]
6. Development of live-attenuated arenavirus vaccines based on codon deoptimization.
Cheng BY; Ortiz-Riaño E; Nogales A; de la Torre JC; Martínez-Sobrido L
J Virol; 2015 Apr; 89(7):3523-33. PubMed ID: 25589652
[TBL] [Abstract][Full Text] [Related]
7. Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.
Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
J Virol; 2015 Jul; 89(14):7373-84. PubMed ID: 25972555
[TBL] [Abstract][Full Text] [Related]
8. The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses.
Iwasaki M; Cubitt B; Sullivan BM; de la Torre JC
J Virol; 2016 Jan; 90(6):3187-97. PubMed ID: 26739049
[TBL] [Abstract][Full Text] [Related]
9. Reverse Genetics Approaches to Control Arenavirus.
Martínez-Sobrido L; Cheng BY; de la Torre JC
Methods Mol Biol; 2016; 1403():313-51. PubMed ID: 27076139
[TBL] [Abstract][Full Text] [Related]
10. Arenavirus reverse genetics for vaccine development.
Ortiz-Riaño E; Cheng BYH; Carlos de la Torre J; Martínez-Sobrido L
J Gen Virol; 2013 Jun; 94(Pt 6):1175-1188. PubMed ID: 23364194
[TBL] [Abstract][Full Text] [Related]
11. Reverse genetics approaches to combat pathogenic arenaviruses.
de la Torre JC
Antiviral Res; 2008 Dec; 80(3):239-50. PubMed ID: 18782590
[TBL] [Abstract][Full Text] [Related]
12. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.
Olschläger S; Flatz L
PLoS Pathog; 2013; 9(4):e1003212. PubMed ID: 23592977
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses.
de la Torre JC
Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E57-64. PubMed ID: 19751403
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
[TBL] [Abstract][Full Text] [Related]
15. Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.
Torriani G; Trofimenko E; Mayor J; Fedeli C; Moreno H; Michel S; Heulot M; Chevalier N; Zimmer G; Shrestha N; Plattet P; Engler O; Rothenberger S; Widmann C; Kunz S
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626681
[TBL] [Abstract][Full Text] [Related]
16. Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein.
Cheng BYH; Nogales A; de la Torre JC; Martínez-Sobrido L
Virology; 2017 Jan; 501():35-46. PubMed ID: 27855284
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses.
Amanat F; Duehr J; Oestereich L; Hastie KM; Ollmann Saphire E; Krammer F
mSphere; 2018; 3(3):. PubMed ID: 29720525
[TBL] [Abstract][Full Text] [Related]
18. Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors.
Brisse ME; Ly H
Front Immunol; 2019; 10():372. PubMed ID: 30918506
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses.
Meyer B; Ly H
J Virol; 2016 Apr; 90(8):3810-3818. PubMed ID: 26865707
[TBL] [Abstract][Full Text] [Related]
20. Generation of recombinant arenavirus for vaccine development in FDA-approved Vero cells.
Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
J Vis Exp; 2013 Aug; (78):. PubMed ID: 23928556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
